Kangstem Biotech Co., Ltd.

Kangstem Biotech Co., Ltd. was founded in 2010 with the vision to become the world's leading stem cell company, driven by the determination of all executives and employees to create a 'better tomorrow than today.' The company focuses on developing stem cell therapeutic products for rare and incurable diseases, positioning itself at the intersection of biotechnology and health care. The core business areas of Kangstem Biotech encompass Stem Cell Therapy, with the development of Furestem® aimed at addressing conditions such as Atopic Dermatitis, Rheumatoid Arthritis, and Osteoarthritis. It has also patented the USC-CM (Umbilical cord blood-derived Stem Cell Conditioned Media), proven to contain abundant growth factors. Similarly, the KSB-3 Complete Medium® Kit offers a medium for culturing human mesenchymal stem cells, promoting high proliferation and a uniform cell state. The company also offers a Cell Freezing and Thawing Platform known as CryoSupport, in addition to providing services as a Contract Development Organization and Contract Manufacturing Organization, affirming their commitment to support projects as a "Super Supporter." Furthermore, Kangstem Biotech has ventured into the Health & Beauty (H&B) Business with GD11, a cell bio-derma cosmetic brand integrating patented cord blood stem cell research technology dating back to 1994. The innovative nature and potential impact of the company's products position Kangstem Biotech as an intriguing prospect for venture capital investors seeking opportunities within the biotechnology and healthcare sectors. The company's dedication to addressing rare and incurable diseases through advanced stem cell technology, combined with its diverse product portfolio, makes it a compelling investment avenue in the rapidly evolving healthcare landscape. For more information, visit their website at www.kangstem.com.